We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
10
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
FDA
Food and Drug Administration
- Prometheus Laboratories presented translational research at DDW 2026 supporting development of a next-generation blood-based test for metabolic dysfunction-associated steatohepatitis (MASH) patient identification. - The new approach builds on the company's established FibroSpect biomarker architecture to better identify patients with moderate fibrosis (F2-F3) who are eligible for emerging MASH treatments. - MASH affects up to 20 million people in the United States, with prevalence rising alongside obesity and type 2 diabetes, creating urgent need for scalable diagnostic solutions. - The company plans to launch the next-generation noninvasive blood test later this year to support identification, management and risk stratification of treatment-eligible MASH patients.
